Objectif
European Union Alzheimer's disease (AD) and related dementias affect 5% of persons aged 65-70 years, rising to 20% in those aged 85 and over. The full costs of AD to EU nations are very high. Due to demographic changes within Europe, the prevalence of AD and costs to the EU are likely to increase dramatically over the next four decades. There are currently no effective therapies for AD. Deposition of amyloidal beta peptide (Abita) within the brains of AD patients is believed to be central to the pathogenesis of the disease. Abita is derived by proteolysis cleavage from the precursor protein. APP. Recently, two families pf proteins, the Fe65s and Axis, have been shown to bind to APP and significantly influence APP processing and Abita production. The purpose of this project is to understand further the mechanisms by witch Fee and X11a influence APP processing and Abita production in AD. Another objective of the project is to explore the relevance of a recently discovered phenomenon (molecular misreading) witch causes the accumulation in AD brains of aberrant proteins. This work will lead to the generation of new AD animal models and to relevant knowledge to design innovative therapeutic strategies and new diagnostic tools.
Champ scientifique
Appel à propositions
Data not availableRégime de financement
CSC - Cost-sharing contractsCoordinateur
80131 Napoli
Italie